Cibisatamab is the first T-cell bispecific antibody with a 2-to-1 format, optimized for safety and efficacy, directly binding CEA on tumour cells and CD3 on T cells, regardless of antigen specificity, resulting in increased T-cell infiltration, T-cell activation and tumour-cell killing15. The gene discussed is CEACAM5; the disease is neoplasm.